Loading chat...
MO SB811
Bill
AI Summary
- Permits eligible patients with terminal illnesses to access investigational drugs, biological products, or devices that have completed phase one clinical trials but lack FDA approval for general use
- Requires eligible patients to have considered all FDA-approved treatment options, received a physician prescription or recommendation, and provided written informed consent (or parental/guardian consent if a minor or incapacitated)
- Allows manufacturers to voluntarily provide investigational treatments to eligible patients without compensation or to charge patients for manufacturing costs
- Prohibits state agencies and regulatory boards from revoking or failing to renew a physician's license based solely on recommending investigational drugs to eligible patients
- Makes it a class A misdemeanor for any state official, employee, or agent to block or attempt to block an eligible patient's access to investigational drugs
Legislative Description
Allows for the use of investigational drugs by those with terminal illnesses
Last Action
Voted Do Pass S Veterans' Affairs and Health Committee
3/27/2014
Committee Referrals
Veterans' Affairs and Health2/20/2014
Full Bill Text
No bill text available